Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era

Urology

Volumn 60, Issue 1, 2002, Pages 120-124

  Oefelein, Michael G ^a   Ricchiuti, Vincent S ^a   Conrad, P W ^a   Goldman, Howard ^a   Bodner, Donald ^a   Resnick, Martin I ^a   Seftel, Allen ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; DIETHYLSTILBESTROL; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANAMNESIS; ANDROGEN INDEPENDENT PROSTATE CANCER; ARTICLE; BLOOD LEVEL; BODY MASS; BONE METASTASIS; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FRACTURE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NOMOGRAM; OBESITY; ORCHIECTOMY; PHARMACOLOGICAL BLOCKING; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BODY MASS INDEX; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FRACTURES, BONE; FRACTURES, SPONTANEOUS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036296523     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01633-3     Document Type: Article

References (28)

1. Cancer Statistics, 2000
2. Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era
3. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the medical research council trial
4. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
5. Prognostic factors in stage D2 prostate cancer: Important implications for future trials - Results of a cooperative intergroup study (INT.0036)
6. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer
7. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate
8. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system
9. Statistical considerations when assessing outcomes following treatment for prostate cancer
10. New Weight Standards for Men and Women
11. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
12. Predicting radionucleotide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters
13. Nonparametric estimations from incomplete observations
14. Regression models and life tables
15. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostate cancer
16. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
17. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol
18. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin: Results on 49 cases from a multicentre study
19. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853)
20. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma
21. Osteoporosis due to androgen deprivation therapy in men with cancer
22. Nutritional and socioeconomic factors in relation to prostate cancer mortality: A cross-national study
23. Pathogenesis of the decreased androgen levels in obese men
24. Similarities of prostate and breast cancer: Evolution, diet and estrogens
25. Body size and prostate cancer: A 20 year follow-up study among 135,006 Swedish construction workers
26. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ rural health study (United States)
27. Body mass index, height and prostate cancer mortality in two large cohorts of adult men in the United States